New York, NY -- (SBWIRE) -- 01/17/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Graphic Packaging Holding Company (NYSE:GPK), CYS Investments Inc (NYSE:CYS), Orexigen Therapeutics, Inc (NASDAQ:OREX), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)
Graphic Packaging Holding Company (NYSE:GPK) showed a volume of 1.97 million shares by the end of last trade whereas the average volume of the stock remained 2.43 million shares. The stock opened the session at $9.40 but then moved to $9.35. At that price, the stock showed a negative performance of -0.53%. Graphic Packaging Holding Company (GPHC) is a provider of packaging solutions for a variety of products to food, beverage and other consumer products companies. It is also a producer of folding cartons and coated unbleached kraft paperboard, coated-recycled board and multi-wall bags. The Company operates in two business segments: paperboard packaging and flexible packaging.
Will GPK Get Buyers Even After The Recent Rally? Find Out Here
CYS Investments Inc (NYSE:CYS) opened the session at $7.62 and closed the session at $7.58. The stock showed a negative performance of -0.66% in previous trading session. Traded with volume of 1.94 million shares in the prior session and the average volume of the stock remained 3.12 million shares. CYS Investments, Inc. is a specialty finance company created with the objective of achieving consistent risk-adjusted investment income. The Company invests in Agency residential mortgage-backed securities (RMBS) collateralized by fixed rate single-family residential mortgage loans (typically 15, 20 or 30 years), adjustable-rate mortgage loans (ARMs), which typically have coupon rates that reset monthly,
Has CYS Found The Bottom And Ready To Gain Momentum? Find Out Here
Orexigen Therapeutics, Inc (NASDAQ:OREX) opened the session at $6.75 and closed the session at $0.276. The stock showed a negative performance of -0.30% in previous trading session. The beta of the stock remained 2.11. Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety,
Why Should Investors Buy OREX After the Recent Fall? Just Go Here and Find Out
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) the stock decreased -2.68% and finished the session at $6.17. Traded with volume of 1.92 million shares in the prior session and the average volume of the stock remained 2.38 million shares. Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer.
Will MACK Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)